Why the study?
What are the available pharmacologic agents for the prophylaxis and treatment of acute ischemic complications of PTCA?
Population
Patients undergoing percutaneous transluminal coronary angioplasty (PTCA)
Design
Review
Authors
Loading...
Supports adjunctive GP IIb/IIIa use in PTCA; leaves open optimal integration with contemporary devices and regimens.
What are the available pharmacologic agents for the prophylaxis and treatment of acute ischemic complications of PTCA?
This review summarizes the evolving landscape of pharmacologic therapies to prevent acute ischemic complications during PTCA, highlighting the emerging efficacy of glycoprotein IIb/IIIa inhibitors.
Wheeldon et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: